U.S. markets closed
  • S&P 500

    4,228.48
    -55.26 (-1.29%)
     
  • Dow 30

    33,706.74
    -292.30 (-0.86%)
     
  • Nasdaq

    12,705.21
    -260.13 (-2.01%)
     
  • Russell 2000

    1,957.35
    -43.38 (-2.17%)
     
  • Crude Oil

    89.91
    -0.59 (-0.65%)
     
  • Gold

    1,760.30
    -10.90 (-0.62%)
     
  • Silver

    18.97
    -0.50 (-2.56%)
     
  • EUR/USD

    1.0044
    -0.0048 (-0.47%)
     
  • 10-Yr Bond

    2.9890
    +0.1090 (+3.78%)
     
  • GBP/USD

    1.1823
    -0.0109 (-0.92%)
     
  • USD/JPY

    136.9300
    +1.0680 (+0.79%)
     
  • BTC-USD

    21,132.65
    -1,685.18 (-7.39%)
     
  • CMC Crypto 200

    504.88
    -36.72 (-6.78%)
     
  • FTSE 100

    7,550.37
    +8.52 (+0.11%)
     
  • Nikkei 225

    28,930.33
    -11.81 (-0.04%)
     

Costa Rica signs COVID-19 vaccine deal with Pfizer and BioNTech

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

SAN JOSE, Dec 3 (Reuters) - Costa Rica has signed an agreement with pharmaceutical companies Pfizer Inc and its German partner BioNTech SE for the manufacture and delivery of 3 million COVID-19 vaccines next year, the office of President Carlos Alvarado said on Thursday.

Deliveries will be made throughout the four quarters of 2021, as established in an initial agreement announced on Oct. 1, the president's office said in a statement.

The deal will allow Costa Rica to provide two doses to 1.5 million people and follows accords with AstraZeneca and the Covax mechanism backed by the World Health Organization. In total, the agreements should cover about 3 million people, or almost 60% of the Costa Rican population.

The Central American country has so far registered some 142,505 cases of coronavirus and 1,757 related deaths. (Reporting by Alvaro Murillo; Editing by Leslie Adler)